- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE readies new Logiq alpha line
GE Medical Systems of Milwaukee is preparing for the commercialintroduction of two new ultrasound scanners, the first membersof a new Logiq alpha family of analog black-and-white systemsfor the entry-level and mid-range segments.Designed and produced by
GE Medical Systems of Milwaukee is preparing for the commercialintroduction of two new ultrasound scanners, the first membersof a new Logiq alpha family of analog black-and-white systemsfor the entry-level and mid-range segments.
Designed and produced by GEMS India, Logiq alpha 100 is a small,portable scanner that features a software-controlled architecturewith continuously adjusted dynamic focus for echo-sensitive, 256-shadegray-scale images, according to the company. GE included informationabout the scanner in its press kit at this month's European Congressof Radiology meeting in Vienna.
Logiq alpha 100 weighs 9.8 kg and is compatible with advancedconvex and microconvex probes. The system is suitable for a widerange of studies, including ob/gyn, gastroenterology, and urology,according to GE.
GE's Japanese subsidiary, YMS, has started sales of both Logiqalpha 100 and another new member of the Logiq alpha series, Logiqalpha 200, according to Comline News Service. Logiq alpha 200features an aperture area for wave emission and reception 1.7times as wide as conventional systems. Logic alpha 200 receivedFood and Drug Administration clearance in August 1996.
As of press time, GE ultrasound executives could not be reachedfor comment on whether the Logiq alpha line will be sold in theU.S.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
